Pantoprazole (Actavis) is a medicine containing the active ingredient(s) pantoprazole. On this page you will find out more about Pantoprazole (Actavis), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: pantoprazole
Over 65 years of age?
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Information for medicine and pack size:
Pantoprazole (Actavis) 40 mg enteric tablet, 30
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion.. Duodenal ulcer.. Gastric ulcer.. Reflux oesophagitis.. Gastrointestinal lesions refractory to H2-blockers.. Zollinger-Ellison syndrome.. Patients whose gastric or duodenal ulceration is not associated with ingestion of NSAIDs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.. For eradication of Helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxycillin or clarithromycin and metronidazole or amoxycillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see Dosage and Administration).. Pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of H. pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.
Table of characteristics
Dark yellow, elliptical, biconvex, enteric-coated tablets
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, enteric coated|
|Route of administration||Oral|
30: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||See Product information for shelf life|
|Life time||4 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 January 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.